The FemTech industry’s approach to PMOS

The article discusses the global renaming of Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS) to better reflect its multisystem nature. It then analyzes India's FemTech industry's response, highlighting its integrated care models and market growth. However, the article critically examines the limitations of privatized FemTech care, such as issues of accessibility, market volatility, and the need for broader public healthcare reforms, improved medical education, and consideration of environmental factors for long-term solutions to chronic women's health conditions.